Table 2.
Our study | NACDG study* | |
---|---|---|
Number of patients (sample size) | 2138 | 5594 |
Prevalence of 2+/3+ammonium persulfate reactions | 2.7% | 0.75% |
Patients with definite and probable clinical relevance of ammonium persulfate allergy | 3/61 (21%) | 26/97 (26.8%) |
*North American Contact Dermatitis Group Patch Test Results: 2015-2016[8]